LIN, GLORIA HOI YING,VILLER, NATASJA NIELSEN,WONG, MARK MICHAEL,WINSTON, JEFFREY TODD,UGER, ROBERT ADAM
申请号：
CA3093603
公开号：
CA3093603A1
申请日:
2019.03.08
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPaFc is enhanced in the presence of daratumumab. Specific combinations include SIRPaFc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
